Try our beta test site
309 studies found for:    Open Studies | "Triplets"
Show Display Options
Rank Status Study
21 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions: Drug: CDX-011;   Drug: Capecitabine
22 Recruiting Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: Pembrolizumab;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Normale Saline Solution
23 Recruiting Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Condition: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Interventions: Drug: MCS110;   Drug: carboplatin;   Drug: gemcitabine
24 Recruiting Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Condition: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: Radiation: external beam radiation therapy;   Drug: cisplatin;   Procedure: Biopsy of Target Tumor
25 Recruiting A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130)
Condition: Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Nab-Paclitaxel;   Drug: Placebo
26 Not yet recruiting Safety and Efficacy Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Condition: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Intervention: Drug: OTS167PO
27 Available Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
28 Recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
29 Recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
30 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
31 Recruiting Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Conditions: Breast Cancer;   Metastatic Triple Negative
Interventions: Drug: Pembrolizumab;   Radiation: Radiotherapy
32 Recruiting Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Conditions: Triple-Negative Breast Cancer;   Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Cisplatin
33 Not yet recruiting A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC).
Condition: Triple Negative Breast Cancer
Intervention: Drug: BLEX 404 Oral Liquid
34 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
35 Recruiting Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms;   Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib;   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis
36 Recruiting Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Conditions: Advanced Melanoma;   Triple-Negative Breast Cancer
Interventions: Biological: Imprime PGG;   Drug: Pembrolizumab
37 Recruiting Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Conditions: Triple-Negative Invasive Breast Carcinoma;   Residual Tumor
Interventions: Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation
38 Recruiting Huaier Granule in Treating Women With Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Huaier Granule
39 Not yet recruiting Ribociclib and Bicalutamide in AR+ TNBC
Condition: Triple Negative Breast Cancer
Interventions: Drug: ribociclib;   Drug: Bicalutamide
40 Recruiting Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Condition: Triple Negative Breast Cancer
Interventions: Drug: Everolimus;   Drug: Eribulin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.